Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species
MDM4 rs4245739 A > C polymorphism appears to be associated with decreased cancer risk
analyses indicated that rs4245739 polymorphism in the MDM4 gene may play an important role in the etiology of cancer
analysis of linear and stapled peptides comprising 6-Me-tryptophan provides mechanistic insight into dual Mdm2 (show MDM2 ELISA Kits)/Mdm4 antagonism and confirms L98 of Mdm4 as a mutable steric gate. The results also highlight a possible role of the flexible hinge region in determining Mdm2 (show MDM2 ELISA Kits)/Mdm4 plasticity
we have herein demonstrated that ERalpha (show ESR1 ELISA Kits) expression associates with MDM4 and MDM2 (show MDM2 ELISA Kits) gene expression in primary breast invasive carcinoma samples
It is now clear that functional p53 (show TP53 ELISA Kits) is critical to protect the genome from alterations that lead to tumorigenesis. The current understanding of the multiple ways p53 (show TP53 ELISA Kits) contributes to genome stability and how two of its negative regulators, Mdm2 (show MDM2 ELISA Kits) and Mdmx, induce genome instability will be described. [review]
results revealed an allosteric ligand-binding mechanism of the N-terminal domain of MdmX in which the ligand initially interacts with a compact core, followed by augmenting intermolecular interactions with intrinsic flexible regions
Complex alterations of HDM4 proteins, which are critical regulators of cell cycle progression, are frequent defects in AML (show RUNX1 ELISA Kits) and HG-MDS (show PAFAH1B1 ELISA Kits) cases. The overall rates of detection of HDM4 expression in the present study, 92% in AML (show RUNX1 ELISA Kits) and 52% in MDS (show PAFAH1B1 ELISA Kits), respectively, indicate that HDM4 is a potential therapeutic target in patients with these diseases.
MDM4 rs1380576 G variant is associated with gastric cancer.
These results demonstrate that cisplatin-mediated p53 (show TP53 ELISA Kits)(V172F) mutation regulates p53 (show TP53 ELISA Kits) stability at the normothermic temperature, but it is the increased recruitment of MDM4 by the homomeric or heteromeric mutant p53 (show TP53 ELISA Kits)(V172F) complex that inhibits p53 (show TP53 ELISA Kits)-dependent transactivation. This represents a novel cellular mechanism of p53 (show TP53 ELISA Kits) inhibition, and, thereby, induction of cisplatin resistance
MDM4 protein is frequently abundant in the context of mutant p53 (show TP53 ELISA Kits) in basal-like breast cancer (BC) samples. MDM4 plays a critical role in the proliferation of these BC cells. MDM4 is crucial for the establishment and progression of tumours.
Data indicate that knockdown of the Mdm2 (show MDM2 ELISA Kits) and Mdm4 caused dramatic accumulation of mutant p53 protein (show TP53 ELISA Kits).
crystal structure of N-terminal domain of Mdmx bound to 15-residue p53 (show TP53 ELISA Kits) peptide was determined; structure reveals that although principle features of Mdm2 (show MDM2 ELISA Kits)-p53 (show TP53 ELISA Kits) interaction are preserved, the Mdmx hydrophobic cleft on which the p53 (show TP53 ELISA Kits) peptide binds is altered
The p53 (show TP53 ELISA Kits)-null mice with the highest level of Mdm4 tended to have multiple tumours. Mdm4 transgenic mice in various genetic backgrounds shows synergy in tumour development in vivo. Mdm4 may thus serve as a therapeutic target in cancers.
These findings suggest that Mdm2 (show MDM2 ELISA Kits) splice isoforms may play critical roles in the regulatory loop of p53 (show TP53 ELISA Kits)/Mdm2 (show MDM2 ELISA Kits)-Mdm4 via a RING domain-mediated biochemical mechanism.
both MDM2 (show MDM2 ELISA Kits) and MDMX deletion-caused pancreatic defects are completely rescued by loss of p53 (show TP53 ELISA Kits), verifying the crucial role of the MDM2 (show MDM2 ELISA Kits) and/or MDMX in regulating p53 (show TP53 ELISA Kits) in a spatio-temporal manner during the development, functional maintenance, and related disease progress of endocrine pancreas.
we failed to detect any increase in p53 (show TP53 ELISA Kits) level in mutant oocytes, nor any other apoptotic marker, introgression of this targeted invalidation in p53 (show TP53 ELISA Kits)-/- mice restored the fertility of females. This study is the first to show that Mdm2 (show MDM2 ELISA Kits), but not Mdm4, has a critical role in oocyte survival and would be involved in premature ovarian insufficiency phenotype.
Data show that the Mdm4-p73 (show ARHGAP24 ELISA Kits) axis cannot override the dominant role of p53 (show TP53 ELISA Kits) in development and tumorigenesis and that Mdm4 and p73 (show ARHGAP24 ELISA Kits) interaction during development and tumorigenesis suggests new insight into the role of p53 (show TP53 ELISA Kits) family members.
MDM4/HIPK2 (show HIPK2 ELISA Kits)/p53 (show TP53 ELISA Kits) cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response.
MDMx degradation associated with neuronal death occurs via caspase (show CASP3 ELISA Kits) activation in neurons, and that the progressive loss of MDMx protein represents a potential mechanism of Abeta (show APP ELISA Kits)-induced neuronal death during disease progression in AD
our results show MDM4-MDM2 (show MDM2 ELISA Kits)/p53 (show TP53 ELISA Kits)-IGF1R (show IGF1R ELISA Kits) as an original regulatory mechanism for CNS regeneration
Increased Mdm4-S mRNA levels might correlate with more aggressive cancers without encoding significant amounts of a potential oncoprotein.
results reveal a novel p53 (show TP53 ELISA Kits)- and Mdm2 (show MDM2 ELISA Kits)-independent oncogenic function of Mdmx that provides new insight into the many cancers that overexpress Mdmx.
This gene encodes a nuclear protein that contains a p53 binding domain at the N-terminus and a RING finger domain at the C-terminus, and shows structural similarity to p53-binding protein MDM2. Both proteins bind the p53 tumor suppressor protein and inhibit its activity, and have been shown to be overexpressed in a variety of human cancers. However, unlike MDM2 which degrades p53, this protein inhibits p53 by binding its transcriptional activation domain. This protein also interacts with MDM2 protein via the RING finger domain, and inhibits the latter's degradation. So this protein can reverse MDM2-targeted degradation of p53, while maintaining suppression of p53 transactivation and apoptotic functions. Alternatively spliced transcript variants encoding different isoforms have been noted for this gene.
double minute 4 protein
, mdm2-like p53-binding protein
, p53-binding protein Mdm4
, protein Mdm4
, MDM4-related protein 1
, double minute 4, human homolog of; p53-binding protein
, protein Mdmx
, Mdm4, transformed 3T3 cell double minute 4, p53 binding protein
, double minute 4 homolog
, transformed mouse 3T3 cell double minute 4